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ABSTRACT 
 
Background: Sub Saharan Africa hosts 90% of the worlds Human Immunodeficiency Virus 
infected children, and in 2007 an estimated 150,000 of these were Kenyan (UNAIDS, 2007). 
Baseline neuropsychological performance is a strong predictor of their diseases progression (Van 
Rie et al, 2006). There is no data on the baseline neurodevelopment (ND) status of Human 
Immunodeficiency Virus infected children in Kenya. Interventions to minimise morbidity and 
improve quality of life are routinely not instituted in Kenya.  
 
Aim: The aim was to determine the prevalence, spectrum and severity of ND delay among a 
cohort of HIV infected Kenyan eligible for HAART initiation but had not received HAART 
previously children at Kenyatta National Hospital Comprehensive Care Center.  
 
Methods: This was a prospective observational cohort study carried out at the Kenyatta 
National Hospital, comprehensive care center, in Nairobi, Kenya. Bayley Scales of Infant 
Development third edition (BSID III) was carried out on 36 highly active anti-retroviral therapy 
(HAART) naïve HIV infected children aged between two weeks and 36 months, about to start 
HAART. These had met all eligibility criteria for HAART according to the KNH CCC protocols 
and were due to start the therapy.  Study subjects were scheduled to have monthly bailey scales 
assessments to a maximum of at least six months post HAART. This was to enhance follow  up 
as only the initial and sixth month assessment was crucial for data analysis. The children 
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underwent laboratory tests and other clinical services in accordance to the hospitals standard of 
care for HIV children. 
 
Results: Thirty two - out of thirty - six children with HIV had neurodevelopment delay in at 
least one of the five constructs assessed by the BSID III at baseline.  In descending order of 
frequency ND was most common in motor, language, cognitive and adaptive BSID III constructs 
respectively. The child aged 18 months and older demonstrated more frequent ND delay in all 
constructs measured except motor while secondary and above maternal education level was 
associated with worse cognitive performance of this cohort.   
 
 
Cognitive, language and social emotional scores improved in the 12 children who completed 
follow up for at least six months of HAART. The clinical significance of this data is the fact that 
even after 6 months of HAART patients still fell in the ND delayed category. This shows HAART 
alone is not sufficient to address ND problems. This data is of clinical significance but further 
research needs to be done to validate its statistical significance.  HAART had no effect in 
improving motor delay in these twelve children. 
 
Conclusion: Neurodevelopment delay in this cohort of Kenyan children with HIV is prevalent; 
83.3% motor delay, 66.6% language delay, 61.2% cognitive delay, 60.6% adaptive delay and 
36.4% socio-emotional delay. All facets of ND delay as measured by the BSID III are affected. 
The magnitude of delay falls in the range that would benefit from early interventional 
rehabilitation. Data of the effect of highly active antiretroviral provision in this cohort is minimal 
but it shows that these drugs alone are not enough to manage the delay. Further research needs to 
be done to validate this point.  
 vii 
ACKNOWLEDGEMENT 
 
My sincere gratitude goes to;- 
1) My supervisors Dr Joanne Potterton of Witwatersrand University and Dr Elizabeth 
Maleche Obimbo of University of Nairobi for guiding me through the research process 
2) Nestle Nutrition Africa for providing the funding to buy the Bayley Scales of Infant 
development. 
3) My gratitude goes to all the Kenyan mothers and children who participated in this study 
making these results possible. 
4) University of Witwatersrand 
5) University of Nairobi department of Paediatrics 
6) Kenyatta National Hospital comprehensive care center 
7) Mr Alex Wambua Mwaniki for statistical help. 
 
 
 
 
 
 
 
 
 viii 
TABLE OF CONTENTS 
 
DECLARATION .............................................................................................................................ii 
DEDICATION ................................................................................................................................iii 
PUBLICATIONS AND PRESENTATIONS ............................................................................. iv 
ABSTRACT ...................................................................................................................................... v 
ACKNOWLEDGEMENT ............................................................................................................vii 
TABLE OF CONTENTS............................................................................................................. viii 
LIST OF TABLES ..........................................................................................................................xii 
LIST OF ABBREVIATIONS ......................................................................................................xiii 
LIST OF DEFINITIONS. ............................................................................................................xiv 
CHAPTER 1...................................................................................................................................... 1 
1.1 INTRODUCTION............................................................................................................ 1 
 
1.1.1 HIV IN KENYA .....................................................................................................................................................................................................................................1 
1.1.2 HIV AND CHILDHOOD OUTCOMES..........................................................................................................................................................................2 
1.1.3 PREDICTORS OF RAPID PROGRESSION OF HIV IN CHILDREN.............................................................................................2 
1.1.4:  HIV AND NEURODEVELOPMENT DELAY IN CHILDREN ..........................................................................................................3 
1.2  RESEARCH QUESTION............................................................................................................... 4 
1.3  AIMS ......................................................................................................................................... 4 
1.4  OBJECTIVES .............................................................................................................................. 4 
 
CHAPTER 2: BACKGROUND AND LITERATURE REVIEW ............................................. 6 
2.1  EPIDEMIOLOGY: HIV AND PMTCT IN KENYA ............................................................................ 6 
2.2  PATHOPHSIOLOGY OF NEURODEVELOPMENT DELAY IN IN HIV INFECTED ............................. 9 
2.2.1  THE HUMAN IMMUNODEFFICIENCY VIRUS..............................................................................................................................................9 
2.2.2  PATHOPHYSIOLOGY OF NEURODEVELOPMENT DELAY .........................................................................................................9 
2.2.3  CLINICAL PRESENTATION ..............................................................................................................................................................................................12 
 
 
 
 
 ix 
2.3  NEURODEVELOPMENT ASSESSMENT IN CHILDREN ......................................... 17 
2.4  HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT AND 
NEURODEVELOPMENT IN HIV INFECTED CHILDREN.............................................. 22 
2.4.1 ANTIRETROVIRAL (ART) DRUGS .............................................................................................................................................................................22 
2.4.2 KENYAN HAART: PROVISION AND PRACTISE .......................................................................................................................................24 
2.4.3 HAART AND NEUROAIDS ...................................................................................................................................................................................................25 
 
2.5  CONCLUSION ................................................................................................................... 27 
 
CHAPTER 3: METHODOLOGY................................................................................................ 28 
3.1  STUDY DESIGN................................................................................................................. 28 
3.2  STUDY POPULATION ..................................................................................................... 28 
3.2.1 INCLUSION CRITERIA .............................................................................................................................................................................................................28 
3.2.2 EXCLUSION CRITERIA............................................................................................................................................................................................................29 
3.3 MATERIALS AND MEASUREMENTS .......................................................................... 29 
 
3.3.1 MAIN RESEARCH TOOL; BAYLEY SCALES OF INFANT DEVELOPMENT 3RD EDITION .......................29 
3.3.2 ROUTINE CLINICAL MEASUREMENTS FOR HIV INFECTED CHILDREN ................................................................30 
 
3.4  CASE DEFINITIONS ........................................................................................................ 31 
3.5  PROCEDURE ..................................................................................................................... 31 
3.5.1 SCREENING VISIT.................................................................................................................................... 31 
3.5.2 SECOND VISIT AFTER ONE WEEK ....................................................................................................... 32 
3.5.3 ANTIRETROVIRAL THERAPY INITIATION APPOINTMENT............................................................ 33 
3.5.4 MONTHLY APPOINTMENT PROCEDURE............................................................................................ 34 
3.5.5 MONTH SIX VISIT PROCEDURES ......................................................................................................... 34 
3.6  STATISTICAL ANALYSIS .............................................................................................. 34 
3.6.1 SAMPLE SIZE CALCULATION ............................................................................................................... 34 
3.6.2 DATA ANALYSIS...................................................................................................................................... 35 
3.7 FUNDING............................................................................................................................. 35 
3.8 ETHICS ................................................................................................................................ 36 
 
 
 
 x 
CHAPTER FOUR: RESULTS...................................................................................................... 37 
CHAPTER FIVE: DISCUSSION OF RESULTS...................................................................... 55 
5.1  PREVALENCE OF NEURODEVELOPMENT DELAY AMONG A COHORT OF 
KENYAN CHILDREN INFECTED WITH HIV ................................................................... 55 
5.2  SPECTRUM OF NEURODEVELOPMENT DELAY AMONG A COHORT OF 
KENYAN CHILDREN INFECTED WITH HIV ................................................................... 56 
5.3 SEVERITY OF NEURODEVELOPMENT DELAY AMONG A COHORT OF 
KENYAN CHILDREN INFECTED WITH HIV ................................................................... 57 
5.4 FACTORS AFFECTING NEURODEVELOPMENT DELAY AMONG A COHORT 
OF KENYAN CHILDREN INFECTED WITH HIV............................................................. 58 
5.4.1 FACTORS AFFECTING OVERALL DELAY PICTURE ......................................................................... 58 
5.4.2  FACTORS AFFECTING SPECIFIC DELAY PARAMETERS................................................................ 59 
 
5.5  LIMITATIONS OF STUDY.............................................................................................. 62 
5.5.1 STUDY DESIGN......................................................................................................................................... 62 
5.5.2 VARIABLES MEASURED ........................................................................................................................ 62 
5.5.3 LOSS TO FOLLOW UP.............................................................................................................................. 63 
 
5.6  RECOMENDATIONS. ...................................................................................................... 63 
 
5.7  CONCLUSION ................................................................................................................... 65 
 
Appendix I:  Ethics Approval University of Witwatersrand ................................................. 67 
Appendix II: Ethics Approval University of Nairobi ............................................................. 68 
Appendix III: WHO 2006 immunological classification for established HIV infection...... 69 
Appendix  IV: Demography form ............................................................................................ 70 
Appendix V: Information Sheet ............................................................................................... 71 
Appendix VI: Consent form...................................................................................................... 72 
Appendix VII: Demographic data extraction sheet ................................................................ 73 
    Appendix VIII: Computer generated Bailey Report. ......................................................... 75 
 
 xi 
LIST OF FIGURES 
 
Figure 1.1: Map of Kenya in Africa        1 
Figure 2.1: Schematic representation of the different encephalopathic courses.  15 
Figure 2.2: HIV life cycle (ANECA, 2006)       23 
Figure 4.1: ND composite scores of study population (From initial assessment).  41 
Figure 4.2: Mortality Distribution By Sex (N = 7)      53 
 
 
 xii 
LIST OF TABLES 
Table 2.1: Qualitative Bayley Composite Score Classifications      20 
Table 3.1: Bayley Classification of ND function.       31 
Table 4.1: Baseline Sociodemographic Characteristics Of Study Population (from initial assessment). 37 
Table 4. 2: Birth Characteristics Of Study Population (from initial assessment)    38 
Table 4.3: Clinical characteristics of study population (from initial assessment)    39 
Table 4. 4: Prevalence Rates For ND Delay Among HIV Infected Children (From initial assessment) 40 
Table 4. 5: Spectrum of ND Delay: Median Bayley Composite Score Summary (From initial assessment) 42 
Table 4.6: Severity of ND Delay: Qualitative Bayley Composite Score Distribution. (From initial assessment) 
          43 
Table 4.7: Factors Associated With Any Delayed ND Score (From initial assessment)   45 
Table 4. 8: Factors Associated With ND delayed Cognitive Scores (From initial assessment  46 
Table 4.9: Factors Associated With ND delayed Language Scores (From initial assessment)  47 
Table 4. 10: Factors associated with ND delayed motor scores (From initial assessment)   48 
Table 4.11: Factors associated with ND delayed SES scores (From initial  assessment)   49 
Table 4.12: Factors associated with ND delayed GAD scores (From initial assessment)   50 
Table 4. 13: Trend In Composite Score Over The Study Period (N = 12) (From both initial and final assessment) 
          51 
Table 4.14: Comparison between demographic characteristics of those who did and did not complete study (From 
initial / baseline assessment visit)          52 
Table 4.15: Neurodevelopmental Delay And Mortality (from initial assessment)    54 
* SES: Socio emotional status 
* GAD:  General Adaptive Behaviour 
 xiii 
LIST OF ABBREVIATIONS 
AAMR American Association of Mental Retardation 
APA  American Psychiatric Association 
BD  Borderline 
BSID III Bayley Scales of Infant Development third edition 
CCC  Comprehensive HIV Care Center 
CNS  Central nervous system 
ELISA Enzyme Linked Immuno Sorbent Assay 
EL  Extremely low 
GAD  General Adaptive behaviour 
HAART Highly active anti  retroviral therapy 
Hb  Hemoglobin 
HIV  Human Immunodefficiency Virus 
KNH  Kenyatta National Hospital 
MTCT Mother to child transmission 
ND  Neurodevelopment 
PCR  Polymerase Chain Reaction 
PMTCT Prevention of mother to child transmission 
SES  Socio emotional status 
TAT  Trans Activator Protein 
WHO  World Health Organization 
 
 xiv 
LIST OF DEFINITIONS. 
 
Neurodevelopment Delay : Below normal or impaired neurodevelopment functioning 
 
Neurodevelopment Construct: Neurodevelopment parameter 
 
Neuroaids   : Neurodevelopment results of HIV AIDS. 
 
 1 
CHAPTER 1 
 
1.1  INTRODUCTION 
 
1.1.1  HIV IN KENYA 
 
The Human Immunodeficiency Virus (HIV) has caused a big pandemic, infecting 33.2 
million people globally (UNAIDS 2007). Of these 2.1 million are children. Worldwide 
this virus caused the death of 290,000 children in 2007 (UNAIDS, 2007). The sub 
Saharan African belt in which Kenya lies hosts 90% of the children living with HIV 
worldwide (UNAIDS, 2007). 
 
 
Figure 1.0-1: Map of Kenya in Africa 
 
 
Kenya is an East African country with a provisional population of 28.9 million people 
(1999 census). She has a fertility rate of 4.9 per woman according to the Kenya 
Demographic Health Survey (KDHS) 2003 version. Her current adult HIV prevalence is 
6.1% (UNAIDS, 2007). The first case of HIV in Kenya was reported in 1984 and by 1995 
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the number had risen to 63,179 (Ministry of Health National Aids Control Council, 
2001).  UNAIDS reported 1.3 million Kenyans were living with HIV in 2007. 
  
1.1.2 HIV AND CHILDHOOD OUTCOMES 
 
The HIV scourge has eroded the gains made on the health of children (Luzuriaga et al, 
2002). In Kenya the under five mortality rate deteriorated from 65 per 1000 live births in 
1998 to 114 per 1000 live births in 2003 (KDHS, 2003). In Kenyan children infected with 
HIV, Mbori Ngacha et al found two year mortality rates of 40.2% and 46.0% in formula 
and breast fed babies respectively (Mbori Ngacha et al, 2001). Obimbo et al observed 
deaths in 52% by two years of age in those infected with HIV during their first year of 
life (Obimbo et al, 2004). These results are in keeping with a meta analysis of 3468 
children from east, west and south Africa  reported 378 (99/1000 child years) deaths 
between the age of one day and 32 months; 35.2% died within the first 12 months (Newel 
et al, 2004).  
 
1.1.3 PREDICTORS OF RAPID PROGRESSION OF HIV IN CHILDREN 
 
To prevent mortality, HIV disease progression indicators are useful, allowing timely 
interventions. Studies have been done to identify predictors of rapid disease progression 
in resource poor settings. Obimbo et al investigating a cohort of 62 Kenyan children 
identified both maternal and childhood indicators of rapid disease progression. The 
childhood factors include early growth faltering, formula feeding, and low CD4 counts 
(Obimbo et al, 2004). A cohort of 80 HIV infected from Abidjan reported that 
independently higher maternal delivery viral loads and higher pediatric viral loads lead to 
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faster HIV disease progression (Rouet et al, 2003). Loannidis et al, 2004 came to a 
similar conclusion. Viral loads are hardly used by most African countries because of their 
prohibitive costs. Children with higher viral loads have been known to progress faster to 
death (Rouet et al, 2003).  
 
1.1.4:  HIV AND NEURODEVELOPMENT DELAY IN CHILDREN 
 
HIV  related neurodevelopment delay has been strongly associated with higher pediatric 
viral loads (Chiriboga et al, 2005; Jeremy et al, 2005). Baseline neuropsychological 
performance is a strong predictor of HIV disease progression (Van Rie et al, 2006). There 
is no data on the baseline ND status of Kenyan HIV infected children. Interventions that 
can prevent morbidity and improve quality of life of HIV infected children  have not been 
instituted into routine care.  A data gap also exists on the effect of ART on the neuroaids 
of sub Saharan African children (Van Rie et al, 2006). 
 
This paper is looking at the prevalence, spectrum and severity of neurodevelopment delay 
among HIV infected Kenyan children. Factors affecting ND delay in these children are 
also studied.  
 
 
 
 
 
 
 
 4 
1.2 RESEARCH QUESTION 
 
What is the prevalence, spectrum and severity of neurodevelopment delay among a 
cohort of HIV infected Kenyan children eligible for HAART initiation but had not 
received HAART previously with specific attention to BSID assessment scores. 
 
1.3 AIMS 
 
To determine the prevalence,  spectrum and severity of neurodevelopment delay among a 
cohort of HIV infected Kenyan children eligible for HAART initiation but had not 
received HAART previously with specific attention to BSID assessment scores. 
 
1.4 OBJECTIVES 
 
1.4.1 PRIMARY OBJECTIVES 
 
To measure using the Bayley Scales of Infant Development the prevalence of  
neurodevelopment delay of a cohort of  HIV positive Kenyan children aged between 2 
weeks and 36 months eligible for HAART initiation but had not received HAART 
previously with specific attention to BSID assessment scores. 
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1. To measure using the Bayley Scales of Infant Development the spectrum of  
neurodevelopment delay of a cohort of  HIV positive Kenyan children aged 
between 2 weeks and 36 months eligible for HAART initiation but had not 
received HAART previously with specific attention to BSID assessment 
scores. 
 
2. To measure using the Bayley Scales of Infant Development the severity of  
neurodevelopment delay of a cohort of  HIV positive Kenyan children aged 
between 2 weeks and 36 months eligible for HAART initiation but had not 
received HAART previously with specific attention to BSID assessment 
scores. 
 
1.4.2 SECONDARY OBJECTIVES 
 
1. To determine factors associated with ND delay among a cohort of  HIV infected 
Kenyan children eligible for HAART initiation but had not received HAART 
previously with specific attention to BSID assessment scores. Factors are: 
- Maternal factors; PMTC prevention, delivery mode, mothers education 
- Child factors; baseline age, sex, WHO staging, immunosuppression by 
CD4%, breastfeeding, HAART. 
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CHAPTER 2: BACKGROUND AND LITERATURE 
REVIEW 
 
Literature Search 
 
The literature search was conducted using both manual and internet resources. Manual 
search was done by the principal investigator with assistance from the Witwatersrand 
university medical school library staff. Websites and search engines used included; 
HINARI, PUBMED and UNAIDS. Keywords included HIV, neurodevelopment, 
cognitive, language, motor, socio-emotional status. 
 
2.1 EPIDEMIOLOGY: HIV AND PMTCT IN KENYA  
 
The Human Immunodeficiency Virus (HIV) has caused has caused a big pandemic in our 
times. UNAIDS estimated that in 2008 alone, the number of Kenyan children under 15 
years of age living with HIV, could be 170,000 (UNAIDS, 2008). The main routes of 
HIV infection in children is Mother to child transmission (MTCT) (ANECA, 2008).  
Infrequent infection modes include direct blood inoculations and sexual contact through 
abuse. Direct inoculation is now a rare infection route, due to improved HIV screening of 
blood products initiated during the nineteen eighties (Willen, 2006). 
 
MTCT is the main infection mode (ANECA, 2006; Luzuriaga et al, 2002) accounting for 
to 90  95% of pediatric HIV infections (ANECA, 2006; Van Rie et al, 2006).  It takes 
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place in utero, perinatally and through breast-feeding (ANECA, 2006; Luzuriaga et al, 
2002; Van Rie et al, 2006; Willen, 2006).  
 
Kenyan data shows that a cumulative 37% of breast feeding mothers infect their babies  
by 24 months if no preventive measures are taken (Nduati et al, 2000; Mbori Ngacha et 
al, 2001). Seventy five percent of MTCT rates in breastfed babies take place within the 
first months of life and account for 15 - 20 % of HIV infections in this population (Nduati 
et al. 2000; Luzuriaga et al, 2002). 
 
MTCT makes the Kenyan pediatric HIV epidemic follow closely that of women. The 
higher the epidemic in Kenyan women of reproductive age the greater the MTCT rates. 
There are up to 1.1 million Kenyan women aged over 15 years living with AIDS in 2008 
(UNAIDS, 2008). The average 2003 figures of those sure of their HIV status stood at 
14% for males and 13% for females (KDHS, 2003) despite the fact that 97 % - 98 % of 
Kenyans had heard about HIV as early as 1994 (National Situational Survey, 1994). 
There is still significant MTCT with most Kenyan mothers breastfeeding their children 
for a mean of 20 months (KDHS, 2003).  Nduati et al, found cumulative MTCT rates of 
36.7% at 24 months in a RCT in which mothers were randomized to breast-feed or 
formula feed their infants in the former group (Nduati et al, 2000). In 1994 only one third 
of women and one fifth of men in Kenya knew about MTCT of HIV (KDHS, 2003). One 
can then deduce that most children born then did not benefit from PMTCT measures.  
 
Prevention of mother to child transmission (PMTCT) programs including anti-retroviral 
therapy (ART) during pregnancy, elective caesarean sections and infant formula feeding 
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have decimated the pediatric HIV epidemic in the developed world (Van Rie et al, 2006; 
Willen, 2006). African countries like Kenya are yet to realize these results.   
 
Since 2004 the Kenyan government has scaled up programs increasing the availability of 
PMTCT services to 60% in 2007. However in 2007 the percentage of pregnant women 
who received treatment to reduce MTCT care was only 9.3% (UNAIDS, 2007). These 
figures support the less than 10% PMTCT global coverage resulting in an increasing 
pediatric epidemic (Van Rie et al, 2006). Many mothers have given birth and breastfed 
their babies without knowing their HIV status contributing to a sizable cohort of Kenyan 
children infected with HIV. These children are part of the 90% of those infected with 
HIV living in the developing world of which little is known of their neurological signs 
and symptomatology (Van Rie et al, 2006).   
 
Infant HIV has been associated with brain function impairment (Van Rie et al, 2006; 
Willen, 2006) especially in those with in utero infection (Van Rie et al, 2006).   
This knowledge can help timely Highly Active Anti-retroviral Therapy (HAART) 
initiation as in up to 18% of infants; it is the first proof of the disease progression to 
AIDS (Van Rie et al, 2006). Before widespread HAART incidence of progressive HIV 
encephalopathy was 13-35% and 35-50% in children diagnosed with the disease and 
AIDS respectively (Van Rie et al, 2006). 
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2.2 PATHOPHSIOLOGY OF NEURODEVELOPMENT DELAY 
IN IN HIV INFECTED 
 
2.2.1 THE HUMAN IMMUNODEFFICIENCY VIRUS 
 
This is a single stranded ribonucleic acid (RNA) virus of the retroviridae family and 
lentiviridae genus. Each virus has two copies of the genome which has two end portions 
and a mid portion. The end portions have long terminal repeats which code for protein 
regulatory genes which include tat one of the key players in HIV neuropathophysiology 
as will be shown later. Mid portion genes are gag coding for core proteins; pol for 
enzymes and Env whose product GP 120 is another important component of the virus 
leading to neuroaids causing events.  
 
2.2.2 PATHOPHYSIOLOGY OF NEURODEVELOPMENT DELAY 
 
The human brain is complicated and intolerable to any compromise. Minimal injury may 
disrupt basic activities like movement, communication and decision making (Olesen et al, 
2006).  HIV affects the Central nervous system (CNS) both directly and indirectly 
(Willen, 2006). Direct CNS HIV infection occurs early in the disease process (Epstein et 
al, 1999;  Van Rie et al, 2006;  Raskino et al, 1999;  Woods et al, 2007;  Foster CJ et al, 
2006;  Lindsey et al, 2008).  The earlier the infection the higher the risk on CNS damage 
(Foster CJ et al, 2006). The virus is easily recovered in perivascular macrophages and 
microglia (Woods et al, 2007; Van Rie et al, 2006; Willen, 2006).  
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The systemic circulation is a source of infected CD 4 lymphocytes, macrophages and 
microglial cells into the brain (Epstein et al, 1999; Van Rie et al, 2006). Vascular 
macrophages get into the CNS because HIV damages the blood - brain barrier (Rickado-
Dukelow et al, 2007; Willen, 2006). Viral proteins including tat, gp 120 and pro 
inflammatory cytokines, tumor necrosis factor á (TNF á) and interleukin 6 (IL 6) are 
thought to disrupt tight junctions of the endothelium (Rickado-Dukelow et al, 2007) a 
fact emphasized by the pallor of white matter being mainly edema rather than myelin 
damage (Epstein et al, 1999). Tat viral protein also affects the barriers monocyte 
migration by exerting oxidative stress on it (Rickado-Dukelow et al, 2007). Infected 
macrophages secrete cytokines like IL 6, monocyte chemoattractant protein 1 (MCP 1), 
platelet activating factor (PAF) and TNF á, all which are implicated in neuroaids 
pathogenesis (Li et al, 2007; Kaul, 2008).  These neurotoxic cytokines trigger 
inflammatory cascades responsible for most of the CNS damage (Epstein et al, 1999; Van 
Rie et al, 2006; Woods et al, 2007; Li et al, 2007; Kaul, 2008).  
 
Astrocytes are another major source of inflammatory cytokines in the HIV infected brain. 
Astrocytic population in the brain is large and its interaction with HIV is postulated to be 
a major factor in neuroaids (Li et al, 2007; Van Rie et al, 2006). These cells do not have 
CD4 receptors but express HIV co receptors namely CCR3, CXCR4 and CCR5 (Li et al, 
2006). Their infection by HIV is low when compared to CD4 lymphocytes and they 
rarely die in neuroaids brain pathology (Li et al, 2007). When exposed to tat or gp 120, 
astrocytes release the same pro inflammatory cytokines as macrophages leading to the 
same neurotoxic cascades (Li et al, 2007; Willen, 2006). Tat and TNF á cause impaired 
glutamate intake while gp 120 leads to a calcium dependent glutamate secretion by 
astrocytes (Li et al, 2007). An infants brain is very plastic and has an over expression of 
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excitatory amino acid receptors the main one of which is glutamate (Epstein et al, 1999; 
Robinson, 2005). The final common pathway for neuronal loss in cytokine triggered 
inflammatory cascades is glutamate mediated excitotoxicity (Epstein et al, 1999; 
Robinson, 2005). This process may be the main reason behind HIV encephalopathy 
because the developing brain is highly sensitive to changes in astrocytic function (Van 
Rie et al, 2006). CNS HIV pathology is therefore a chronic inflammatory state of  
microglial cells (Epstein et al, 1999; Woods et al, 2007)  with reactive astrogliosis 
leading to impaired brain growth in seropositive infants (Epstein et al, 1999).  
 
The glutamate mediated excitotoxicity results in oxidative stress leading to the main 
mechanisms of neuronal and glial injury, apoptosis and axonal degeneration (Epstein et 
al, 1999; Robinson, 2005; Woods et al, 2007). These are present in the whole CNS but 
especially in connections between the basal ganglia and frontal cortex explaining the 
neuropsychological HIV profile of cognitive compromise, motor slowing, executive 
dysfunction and poor encoding and retrieval of memory (Woods et al, 2007). Epstein et 
al, 1999 and Willen 2006 also noted involvement of the basal ganglia and cerebral white 
matter while the radiologic diagnostic signs include calcification of the former and 
cortical atrophy on CT scan (Van Rie et al, 2006; Foster CJ et al, 2006). MRI pathology 
shows white matter abnormality and central atrophy (Van Rie et al, 2006). 
 
Though there is some data on primary HIV damage to neurons, this is not the main stay 
of neuroaids pathophysiology (Epstein et al, 1999; Van Rie et al, 2006; Li et al, 2007).  
 
Viral proteins as noted previously also play a significant role in HIV neuropathogenesis 
(Li et al, 2007; Epstein et al, 1999). One of them, trans activator protein (tat) is a major 
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neurotoxin and works by triggering mitochondrial injury, oxidative stress, inflammatory 
cascades  and binding to integrin receptors (Rumbaugh et al, 2006).  
 
HIV can also affect pediatric neurodevelopment in an indirect fashion. Mechanisms 
involved include opportunistic infections, cerebral vascular disease (Van Rie et al, 2006; 
Willen, 2006) and lymphomas (Van Rie et al, 2006). The interaction of ones genetic 
make up and the environment also determines ones brain function (Fenoglio et al, 2006). 
Enviromental factors shown to cause ND delay include use of drugs or alcohol by the 
mother, poverty, sub standard home environ and low maternal education (Van Rie et al, 
2006; Willen, 2006). Children born to HIV parents are under a lot of stress both from the 
effect of the disease on their bodies and poor environmental support. This is because 
many have socio-economically disadvantaged and infected parents. The late gestation and 
early infancy is a critical period of vulnerability where chronic stress levels lead to 
irreversible damage to the brain including the hippocampus which is involved in learning, 
memory storage, retrieval and general cognitive functions (Fenoglio et al, 2006).  
 
2.2.3 CLINICAL PRESENTATION 
 
Neuroaids in infants occurs before significant immunosuppression and is the initial AIDS 
defining illness in up to 18% of children living with HIV (Van Rie et al, 2006; Van Rie et 
al, 2008;  Willen , 2006; Forster CJ et al, 2006).  Its presentation is affected by factors 
like viral load, advanced maternal disease (Willen, 2006; Van Rie et al, 2006) age at 
assessment and  primary infection, interval between the above temporal measures and 
HAART (Willen, 2006).  
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2.2.3.1 SPECTRUM OF NEURODEVELOPMENT DELAY 
 
 Neural signs and symptoms observed in HIV infected children are many (Willen, 2006).  
It has been noted that HIV pathology is most evident in neural connections between the 
basal ganglia and frontal cortex (Woods et al, 2007). This explains the prototype 
neuropsychological profiling of HIV namely poor executive and memory functioning 
(Woods et al, 2007), slowing of cognitive and motor functions (Willen, 2006; Woods et 
al, 2007; Lindsey et al, 2008). A Brazilian cohort reported encephalitis, progressive 
multifocal leukoencephalopathy, focal signs (hemiparesis and paraparesis), altered tonus, 
cognitive disturbances, intractable headache, seizures and coma (Fragoso et al, 1999). 
Jeremy et al when performing baseline neuropsychological tests  on 473 children reported 
microcephaly, hypertonic diplegia/diparesis and hyperactivity disorder (Jeremy et al, 
2005). Neurodevelopmental disruption thus presents with cognitive, behavioural 
abnormalities (Willen, 2006; Epstein et al, 1999) and motor dysfunction (Epstein et al, 
1999).  
 
2.2.3.2 SEVERITY OF NEURODEVELOPMENT DELAY 
 
HIV neurological presentations have been summarized into 3 syndromes, HIV related 
encephalopathy, CNS compromise and apparently normal (Pizzo and Wilfert, 1994). HIV 
encephalopathy is defined as (1) failure to attain or loss of developmental milestones or 
loss of intellectual ability; (2) impaired brain growth or acquired microcephaly; (3) 
acquired symmetrical motor deficit, in the absence of a concurrent infection other than 
HIV-1, and persisting for at least 2 months (CDC, 1994). HIV related encephalopathy can 
be static, plateau or sub acute with a rapid relentless course and is the result of the virus 
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working on an immature brain (Van Rie et al, 2006; Willen, 2006). Children infected 
through MTCT are at a higher risk of CNS disease with those infected in utero more 
likely to get the worst of the paediatric HIV encephalopathy syndromes (Van Rie et al, 
2006).  
 
Static encephalopathy patients can gain new skills but have a below average score on 
neural developmental (ND) tools. In the plateau type, patients do not loose acquired skills 
but cannot gain any new ones. The worst prognosis is the sub-acute variety where 
previously acquired skills are lost in addition to behavioural abnormality (Pizzo & 
Wilfert, 1994; Willen, 2006). The following diagram summarizes the three known 
disease courses of HIV encephalopathy  
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Figure 2.0-1: Schematic representation of the different encephalopathic courses. 
 
( Pizzo & Wilfert, 1994). 
 
From the European collaborative study of 5209 visits of 161 infected children, 
encephalopathy was associated with HIV disease progression after one year of age 
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(European collaborative study, 2004). This has been corroborated by the fact that low 
cognitive and psychomotor scores are predictors of rapid HIV disease progression 
(Willen, 2006). Severe cognitive and motor delay scores by four months of age is an 
ominous predictor of early death (Van Rie et al, 2006). 
 
2.2.3.3 PREVALENCE OF NEURODEVELOPMENT DELAY 
 
Prevalence of motor, cognition, speech and language delay in HIV infected children has 
been reported to range from eight percent to over 60% (Van Rie et al, 2006).  
 
Rumbaugh et al noted an incidence of cognitive impairments in up to 30% of infected 
persons (Rumbaugh et al, 2006). As noted above, the frontal cortex - which is one of the 
main cognition lobes of the brain - is one of the hardest hit in HIV infection (Woods et al, 
2007). Cognitive delay occurs later in infancy and its presentation is global rather than 
specific (Van Rie et al, 2006). Cognitive tasks performed poorly by HIV infected children 
include sequential processing, spatial memory, auditory and visual immediate recall 
(Willen, 2006). Learning disabilities are also frequent (Willen, 2006).  
 
Motor lesion symptomatology include loss of developmental milestones, symmetric 
pyramidal and extrapyramidal dysfunction (Epstein et al, 1999). In infants motor delay 
especially gross, differentiates between those exposed and infected with HIV (Van Rie et 
al, 2006). Gross motor abnormalities include hypertonic diplegia (Foster CJ et al, 2006). 
Motor malfunction namely reduced bulk, strength and abnormal tone are indicative of 
HIV disease progression (Van Rie et al, 2006; Willen 2006).  
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Language delay has been reported as part of ND abnormality in HIV (Willen, 2006; Van 
Rie et al, 2006; Lindsey et al, 2008). It is mainly expressive (Van Rie et al, 2006; Foster 
CJ et al, 2006).  This fact was corroborated by Wolters et al who realized expressive 
language was more compromised than receptive and more so in encephalopathic children 
with HIV (Wolters et al, 1996). Van Rie et al realised language delay rates of expression, 
84.6%, and comprehension, 76.7%. Language delay occurs before other ND and 
radiological signs, making its assessment useful for early ART initiation and monitoring 
(Van Rie et al, 2008). 
 
Significant behavioural and personality change in pediatric neuoroaids has been 
identified (Wolters et al, 1996; Lindsey et al, 2007). Aetiology is varied and include 
direct HIV neuropathology  like toxin release and structural changes such as basal ganglia 
calcification (Wolters et al, 1996). Indirect effects like genetic or environmental are also 
very influential (Lindsey et al, 2007).  Behavioural assessments in HIV have been 
equivocal according to a systemic review by Van Rie et al, 2006.  Wolters et al however 
showed reduced social and emotional responsiveness in infants (mean age 1.8 years) with 
HIV encephalopathy (Wolters et al, 1996). These children are challenged in purposeful, 
expressive, social emotional and goal directed behavior compounded by and leading to 
poor interpersonal skills and loss or arrest of verbal or motor skills (Wolters et al, 1995). 
 
 
2.3 NEURODEVELOPMENT ASSESSMENT IN CHILDREN 
 
Baseline neuropsychological performance is a strong predictor of HIV disease 
progression and it is directly related to the severity of HIV encephalopathy (Pearson et al, 
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2000 ).  It is important to know each childs ND performance, for as noted previously, it 
may be the first AIDS defining illness before significant immunosuppression  in infants 
(Van Rie et al, 2006; Lindsey et al, 2007). Various standardized ND tools have been 
developed to obtain this data. These include the Bailey Scales and Griffiths scales among 
others.  
 
One such tool which has been standardized to capture development information is the 
Bayley Scales of Infant Development third edition (BSID III). It is an upgrade of the 
second edition and maintains the original nature and purpose of the Bayley scales 
(Bayley N, 2006). This is important because extensive work has been done to standardize 
the second edition for HIV research. BSID III data can then easily compare with results 
of other HIV neurodevelopment studies and can participate in systematic reviews once 
published. This is the reason why the BSID III was chosen for this study as it is without 
any modifications. This assessment tool should be administered by one trained to 
adminster ND assessments.  
 
The mental development index of the second edition formed the backbone of the 
cognitive and language assessment of the latter issue, leading to a correlation of r = 0.60 
and 0.71 respectively.  Correlation between the motor composite of the third edition and 
the psychomotor development index of the second is r = 0.60 (Bayley N, 2006). 
 
The BSID III is a development rather than intelligence assessment test. While the 
division between the two concepts is unclear, BSID III activities are from theoretical 
models of development and empirically validated data at different ages (Bayley N, 
2006). Intelligence data is normalized and results do not change as one gets older. 
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Interpreting both groups of data however involves getting a development or intelligence 
quotient and getting a medical biological or genetic cause of it, if abnormal (Walker et al, 
2006). 
 
Abnormal quotient or development delay, has been defined as two standard deviations 
(SD) or more below mean score in one parameter or two one and half SDs below the 
mean in at least two parameters  (Bayley N, 2006). Another definition includes 
functioning of less than 25% below same aged peers (Bayley N, 2006). The mean in 
development or intelligence tools both of which have been used to asses ND delay in 
children is usually a score of 100 with a SD of about 15. This helps correlate the various 
tools of assessment. The correlation of BSID III and Weischlers III, the main intelligence 
test, is r = 0.79 and 0.82 between the full scale IQ of the former and cognitive and 
language composites of the latter respectively (Bayley N, 2006). American Psychiatric 
Association Diagnostic Statistical Manual  IV  TR (APA DSM  IV  TR) has a 
development or intelligence quotient cut off, of mental retardation or global 
developmental delay, of 70 while the American Association of Mental Retardation 
(AAMR) puts it at 75 (Walker et al, 2006). The latter is useful in planning for 
rehabilitation and is more in line with the Bayley classification of ND function (See table 
3.1 in the case definitions chapter). 
 
BSID III provides information on the cognition, motor, language, social emotional and 
general adaptation of the child tested. Data on the above constructs is presented as either 
raw scores or derived scores. Whereas raw scores are the actual tally of an assessment, 
derived scores are adaptations of the former, allowing for useful statistically backed 
interpretation of the data as described above. This adaptation is based on statistical data 
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realized during tool development. Derived scores include, scaled, composite, percentile, 
developmental age equivalent and growth scores. The latter three scores are useful in 
explaining results to parents as they are easily understood. Scaled are useful in comparing 
development within an individual child while composite are useful in comparing results 
with other measures of ND and are hence the most reported. For the sake of this 
discussion we will deal with only composite scores which can be interpreted as described 
above. 
 
Composite scores range from 40 to 160 with a mean of 100 and SD of 15. These are 
useful in ascertaining how far ones score is from the mean and has a qualitative 
description per range easily understood by parents as shown in table below.   
 
Table 2.0-1: Qualitative Bayley Composite Score Classifications 
Qualitative description Composite score 
 Very superior 130 and above 
 Superior 120  129 
 High average 110  119 
 Average 90  109 
 Low average 80  89 
 Borderline 70 -79 
 Extremely low 69 and below 
 
Using the table above one can classify neurodevelopment delay as those falling in the 
extremely low category only (APA  DSM IV  TR) or those falling in the borderline and 
extremely low category (AAMR classification). The result section while clearly taking 
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into consideration both schools of thought put more emphasis on the latter classification 
so as not to leave out children who can benefit from rehabilitation intervention. This has 
direct implication on the later morbidity and quality of life of the child. 
 
Cognition, language and motor development are objectively measured by the Bayley kit. 
BSID III uses parent filled questionnaires to assess social emotional status and general 
adaptation of the child. 
 
Cognition scale 
 
The BSID III cognition scale is based on the role of play, information processing, number 
concepts and counting on a childs higher functional capabilities. Counting, number 
constancy and cardinality are other aspects tested in BSID III cognition scale. 
 
Language scale 
 
BSID III tests receptive and expressive language. Receptive language includes auditory 
acuity especially when younger. Older childrens understanding and proper response to 
words and requests is also tested. 
 
Motor scale 
 
BSID III motor scales are based on the motor milestones of a typically developing child. 
The motor assessment is divided into both fine and gross motor scales. 
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Social Emotional Status scale 
 
The social - emotional development of infant and young children is identified by 
milestones typically achieved by certain ages. These are based on the six social emotional 
milestone levels by Greenspan.  
 
Adaptive behavior Scale 
 
Parents or legal guardians answer questions that check their childs ability to adapt to 
different aspects of typical daily life. 
 
(Bayley Scale of Infant Development 3rd edition Technical Manual Chapter 1: pages 1 - 
10) 
 
2.4 HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT AND 
NEURODEVELOPMENT IN HIV INFECTED CHILDREN 
 
2.4.1 ANTIRETROVIRAL (ART) DRUGS 
 
Antiretroviral drugs have been developed to help in the management of the HIV 
infection. Their classification is based on their mechanisms of action. Below is a diagram 
of the HIV life cycle and points of action of different classes of ART. 
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Figure 2.0-2: HIV life cycle (ANECA, 2006) 
 
 
From above figure one easily identifies various classes of ART namely; reverse 
transcriptase inhibitors (RTI), protease inhibitors, integrase inhibitors, fusion inhibitors.  
Only the first two classes have been used comprehensively in HIV treatment.  Reverse 
transcriptase inhibitors are sub classified into nucleoside reverse transcriptase inhibitors 
(NTRI)  including zidovudine, stavudine and non nucleoside reverse transcriptase 
inhibitors (NNRTI)  like nevirapine and efavarence. Protease inhibitors include lopinavir 
and ritonavir. 
 
Monotherapy is discouraged as the virus mutates rapidly causing growth of resistant 
populations. HIV is treated through a combination of more than one of the above classes 
of drugs. Highly Active antiretroviral therapy (HAART) is defined as a combination of at 
least three ART drugs usually two NRTIs plus either a protease inhibitor or a NNRTI.  
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2.4.2 KENYAN HAART: PROVISION AND PRACTISE 
 
In the past several years the cost of HAART has dropped considerably in Kenya from a 
monthly figure of 100 - 200 USD in 2002, its currently free for patient and the health 
facility. This was made possible when the government of Kenya got support from the 
Global AIDS program. By June 2004 only 11,000 Kenyans (15 to 49 years) were on ART 
(UNAIDS, 2004).   
 
Most children were unable to access ART until the United States Government 
Presidential Emergency Fund for AIDS Relief (PEPFAR) initiative in 2004. A grant for 
provision of branded ART to patients of Kenyatta National Hospital (KNH) including 
pediatric formulations was awarded to University of Nairobi in October 2004 and from 
January 2005 children were able to access HAART at a cost of USD 1.3 per month at the 
university teaching hospital. HAART provision to children and the health facility is 
currently free. HIV care is dispensed using the comprehensive care clinic (CCC) concept, 
which offers clinical counseling, HAART, and laboratory services to patients.  
 
There are national paediatric HAART guidelines. First line drug combinations include 
Zidovudine   or stavudine with lamivudine and nevirapine. In the second line drug 
combination the two NNRTs are replaced by didanosine and abacavir while nevirapine 
is replaced by ritonavir boosted lopinavir (Ministry of Health, 2004).  
 
KNH uses immunological staging using WHO 2006 classification, in initiating and 
following up pediatric ART. This is the same classification used in the demography of 
this study (appendix III). 
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Goals of treatment are to restore or preserve immunological function and to improve 
clinical parameters, leading to a reduction in morbidity and mortality. All these occur as a 
result of viral suppression. HIV pathology on the neurodevelopment of children has been 
strongly associated with higher viral loads (Chiriboga et al, 2005; Jeremy et al, 2005). 
HAART significantly reduces viral loads but many studies have shown that ND 
functioning is not as dramatically affected (Chiriboga et al, 2005; Jeremy et al, 2005; Van 
Rie et al, 2006; Lindsey et al, 2007).   
 
2.4.3 HAART AND NEUROAIDS 
 
HAART is known to keep the cognitive function intact in high risk HIV patients 
(Deutsch et al, 2001). It is also known to reverse CNS manifestations and reduce risk and 
severity of HIV encephalopathy (Van Rie et al, 2006).  Raskino et al, 1999 using various 
ND tests, to cater for age, one of which is the BSID II noted that combination ZDV and 
DDI treatment improved performance in neurocognitive, head circumference and motor 
assessments than either drug as a monotherapy. Since then many studies have proven 
HAART improves ND delay. Chiriboga et al, 2005 reported progressive HIV 
encephalopathy as an infrequent and reversible outcome of HIV that responds to 
HAART. They however realized that residual motor and cognitive damage persisted 
necessitating the need for special education. Van Rie et al, 2006 reports high rates of 
residual behavioral neurologic, cognitive and scholastic abnormalities. She also noted a 
high risk of relapse. Residual is lingering CNS abnormality after being on HAART. 
Relapse is recurrence of a CNS abnormality that had improved or disappeared after 
starting HAART. Lindsey et al, 2007 using the Bayley scales concludes that limited ND 
 26 
improvements exist despite viral suppression and positive outcomes in immunological 
and survival status.  Jeremy et al, 2005 seem to agree with the above point in her 
conclusion that while the efficacy of current anti retroviral therapy (ART) in reducing 
viral load is good they do not optimally remedy neuropsychological damage at least 
within one years follow up. This paragraph is not contradictory but points to the fact that 
there must be more to HIV CNS manifestations than viral load reduction only. 
 
Efficacy of ART in the CNS is affected by the blood brain barrier (BBB) which creates 
compartmentalization and hence emergence of distinct viral populations (Van Rie et al, 
2006; Shanbhag et al, 2005). These CNS viral populations can cause neurocognitive 
abnormalities despite successful antiviral performance in other body tissues (Deutsch et 
al, 2001; Lindsey et al, 2007). Variability in the ability of ART drugs to cross the BBB is 
the main explanation to the above with protease inhibitors having the poorest CNS 
penetration (Van Rie et al, 2006; Lindsey et al, 2007). Sub optimal ART CSF penetration 
then occurs (Shanbhag et al, 2005). 
 
 The HIV also benefits from the relatively long lifespan of infected microglia, 
macrophages and astrocytes as compared to CD4 lymphocytes. This frustrates the speed 
of clearing this virus from the CNS (Van Rie et al, 2006). 
 
Viral proteins like tat play a role in neuroaids pathogenesis in triggering the inflammatory 
cascades. Their synthesis by HIV infected cells is not affected by current ART regimes 
(Rumbaugh et al, 2006). BBB damage by HIV leading to entry of infected macrophages 
into the CNS is another neuropathological process not affected by HAART (Ricardo-
Dukelow et al, 2007). 
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2.5 CONCLUSION 
 
There is no data on the baseline ND status of Kenyan children infected with HIV. 
Interventions that prevent morbidity and improve quality of life are then not included in 
routine care.  A data gap also exists on the effect of ART on the neuroaids of sub Saharan 
African children. Neurobehavioural assessments can provide information on HIV disease 
progression beyond traditional markers like CD4 count and RNA levels (Van Rie et al, 
2006) optimizing on the timing of HAART initiation reducing morbidity and mortality 
especially in resource poor settings (Willen, 2006). Risk factor evaluation for 
neurocognitive delay in HIV infected children is also warranted (Shanbhag et al, 2005). 
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CHAPTER 3: METHODOLOGY 
 
3.1 STUDY DESIGN 
 
This was a prospective observational cohort study 
 
3.2 STUDY POPULATION 
 
The study population was drawn from the Comprehensive HIV Care Clinic (CCC) of 
Kenyatta National Hospital (KNH). KNH is the biggest public hospital in eastern and 
central Africa. It is the national referral hospital for Kenya and the University of Nairobi 
teaching hospital. The Bayley Scales of Infant Development  3rd edition (BSID III) caters 
for development assessment of children between two weeks and 42 months of age. Since 
the follow up was for at least six months, HIV infected children aged between two weeks 
and 36 months were eligible for the study. All children underwent HIV antibody testing 
and those under 18 months had their diagnosis confirmed using HIV DNA Polymerase 
chain reaction (PCR). 
 
3.2.1 INCLUSION CRITERIA 
 
 Presence of legal guardian 
 Aged between two weeks and 36 months 
 Confirmed positive HIV infection by PCR if <18 months or positive HIV 
ELISA if >18 months. 
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 HAART naive at enrolment. Patients exposed to short course 
antiretrovirals for PMTCT but not HAART were included. 
 World Health Organization (WHO) clinical stage two, three or four. 
 From treatment records should have shown good compliance to two 
immediate previous clinical appointments. 
 Informed consent from parent/guardian to participate in study 
 
3.2.2 EXCLUSION CRITERIA 
 
 HAART experienced. 
 Other CNS disease e.g. cerebral palsy, post meningitic neurological 
disease 
 Below two weeks of age or over 36 months of age. 
 
3.3 MATERIALS AND MEASUREMENTS 
 
3.3.1 MAIN RESEARCH TOOL; BAYLEY SCALES OF INFANT 
DEVELOPMENT 3RD EDITION 
 
This is a standardized tool used to measure the following neurodevelopmental constructs; 
1. Cognition 
2. Language both receptive and expressive 
3. Motor both fine and gross 
4. Social emotional status 
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5. Adaptive behavior Scale. Abilities measured here fall under following tittles; - 
communication, community use, functional pre-academics, home living, health 
and safety, leisure, self care, self direction, social and motor.  
 
The BSID III came with a scoring computer program which was used to convert the raw 
scores into derived scores used for statistical analysis. 
 
3.3.2 ROUTINE CLINICAL MEASUREMENTS FOR HIV INFECTED 
CHILDREN   
 
3.3.2.1 ANTHROPOMETRIC TOOLS 
 
Ruler; measure recumbent length in those < 24 months 
Stadiometer; measure height in those > 24 months.  
Weighing scales; measure weight 
 
3.3.2.2 LABARATORY TESTS 
 
The following tests are carried out prior to HAART initiation, and for monitoring 
response to and for adverse effects of HAART. 
 
CD4 counts; at baseline and after 6 months of followup, measure immune status. 
Full hemogram , alanine transaminase; at baseline month one and every three months 
thereafter.  Serum creatinine; at baseline and every six months. 
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3.4 CASE DEFINITIONS 
 
ND delay is defined as those children falling in the borderline and extremely low Bayley 
composite qualitative definition (See table 2.1) This is supported by the Bayley 
classification of Neurodevelopment function as shown in the table below. 
 
Table 3.0-1: Bayley Classification of ND function. 
 
ND Functional classification Development Quotient 
Accellerated > 115 
Normal 85  115 
Mild Delay 70  84 
Severe Delay < 70 
 
(Bayley N,1993) 
 
3.5 PROCEDURE 
 
3.5.1 SCREENING VISIT 
 
The primary investigating doctor, identified potential eligible study subjects by studying 
patients records, interviewing their parents and or legal guardians. Once eligibility was 
established the study was explained to the parents or legal guardians and a request for 
consent put in. Once a written consent was granted, a demography form and data 
 32 
extraction sheet was filled through parental or legal guardian interview and study of the 
hospital file. Routine clinical and initial screening tests were then ordered, which 
included a confirmatory HIV ELISA if the patients file had no data on this. HIV PCR 
was done on samples from children less than 18 months with a positive HIV antibody 
test. Other routine blood tests requested were full hemogram, alanine transferase, serum 
creatine and CD4 count and percentage. The child was then led to a phlebotomist who 
withdrew a total of five milliliters of blood in three tubes from the child. For children less 
than 18 months with no positive ELISA report the laboratory was requested to store cells 
for one week for PCR testing. The patient is then given one to two weeks return 
appointment. This is part of the Study site, KNH CCC, procedure for starting HAART. 
This is because for patients under 18 months it took one week to get PCR results hence 
the one to two weeks appointment. 
 
3.5.2 SECOND VISIT AFTER ONE WEEK 
  
Labaratory test results are discussed with the parents and or legal guardians. Those 
eligible (HIV infected confirmed by ELISA if over 18 months and PCR if under 18 
months and WHO stage two to four) were enrolled into the study.  
 
Neuropsychological assessment using the Bayley scales was carried out by Dr 
Madumadu Kigira the study doctor. She is the only one who did the BSID assessment. 
This standardised tool comes with a kit which helps one collect raw data. The kit being 
standardised helped deal with intra observer bias as results were based on rules of the 
scales rather than subjectivity of the assessor. The kit also came with a computer program 
that converts raw scores into derived scores and stores them. All data is currently in the 
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computer. It also prints reports and graphs. Data was coded to identify each study patient 
with a code rather than name and this was what was analysed with the help of a 
statistician. Each patient had a code that had MSC for degree, ND for neurodevelopment 
and registration number for example MSCND001 for the first study subject. The BSID III 
was carried out on the child early in the clinical visit to optimize co-operation from the 
child before he or she got stressed by painful and uncomfortable procedures.  
 
Baseline anthropometric measurements were carried out and recorded by the nursing staff 
as part of their triaging process in keeping with the CCC HAART management protocols. 
A HAART initiation appointment was then scheduled to those eligible. Monthly follow 
up visits scheduled as standard CCC protocol for new HAART patients were set up to 
enhance adherence to the study. The BSID III does allow for monthly growth score 
charting and monitoring. The growth score charts were then explained and given to the 
parents at the end of the study period. One week to the monthly appointment a reminder 
telephone call was made if parents or legal guardians owned a phone.  
 
3.5.3 ANTIRETROVIRAL THERAPY INITIATION APPOINTMENT 
 
The patient followed the Kenyatta National Hospital comprehensive care clinic procedure 
of being absorbed into the HAART program. This involves two to three counseling 
appointments by professional counselors. Once the counselor is comfortable with the 
parents or guardians understanding of HAART, the patient was sent to the CCC doctor 
who prescribed an appropriate HAART regime after studying the laboratory test results. 
The CCC pharmacy dispensed the drugs and reinforced adherence counseling. 
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3.5.4 MONTHLY APPOINTMENT PROCEDURE 
 
At each monthly visit anthropometric tests (height or length, and weight) were taken. 
Adheherence to HAART issues was evaluated. Any clinical problems were treated. A 
BSID III assessment was also done to get growth chart monitoring results for the parents. 
The patient then proceeded to the KNH CCC procedure of HAART follow up. This 
included a full haemogram and alanine transaminase test at month one and three. Since 
the main aim of these monthly visits was to minimize loss to follow up cases, one week 
to the monthly appointment a reminder telephone call by study doctor was made if 
possible.  
 
3.5.5 MONTH SIX VISIT PROCEDURES 
 
This was the last study appointment and its procedure was similar to the monthly 
appointment without the reminder telephone call for following month. A cognitive 
growth chart was filled in for each child who completed the study and its meaning 
explained to the mother as part of the benefit of participation.  
 
3.6 STATISTICAL ANALYSIS 
 
3.6.1 SAMPLE SIZE CALCULATION 
 
Sample size calculation was based on the first primary objective. Using MS Excel 
Sample size V4 draft and taking into consideration the standard deviation of BSID III 
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composite score which is 15 with a mean of 100, and assuming a drop out rate of 20% 
and a level of confidence of 95%; the minimal sample size calculated was 33 children. 
There was no randomization. All children attending the CCC who met the inclusion 
criteria were eligible. 
 
3.6.2 DATA ANALYSIS 
 
BSID III has a computer program that automatically converts raw scores to 
- scaled scores with a mean of 10 and a SD of 3 
- composite scores with a mean of 100 and a SD of 15 
 
The program also calculates significant differences between the neurodevelopmental 
contructs. Fischers exact and pearsons chi square analysis statistics were calculated 
using the SPSS software. 
 
3.7 FUNDING. 
 
1. Nestle Nutrition covered the cost of the BSID III tools. 
2. The children who participated in this study received their comprehensive HIV 
care at KNH CCC which is supported by the Government of Kenya and the 
United States government PEPFAR initiative. 
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3.8 ETHICS 
 
This research was carried out in Kenya. Ethical committees clearances were obtained 
from the Committee for Research on Human subjects University of Witwatersrand South 
Africa and the Kenyatta National Hospital (KNH) ethical committee, Kenya (See 
appendix one and two respectively).  
 
The study was fully explained to the parents and legal guardians of the child and written 
consent obtained before enrollment. All study participants were offered HAART 
according to the KNH CCC protocol. Study procedures posed no additional risk to the 
child. Blood tests done were in keeping with the standard KNH CCC protocols. No 
interference was made in the routine clinical management of the child by the primary 
KNH CCC doctors. Any clinical condition noted by the researcher requiring immediate 
medical attention was reported to the primary KNH CCC doctors. 
 
All patients had access to free HAART drugs as standard of care of the hospital. Drugs 
were donated under United States government PEPFAR program. Patients were free to 
discontinue from the study at any point according to their wish. No material or financial 
incentives were given to the patients. 
 37 
CHAPTER FOUR: RESULTS 
 
4.1 SOCIODEMOGRAPHIC CHARACTERISTICS OF STUDY 
POPULATION 
Table 4.0-1: Baseline Sociodemographic Characteristics Of Study Population (from 
initial assessment). 
Characteristic Frequency or Median Percentage or Range 
INFANT FACTORS 
Age (in Months) (n = 36)  
< 6 
6  12 
13  18 
19  24 
25  30 
30 + 
7 
14 
4 
4 
6 
1 
19.4% 
38.9% 
11.1% 
11.1% 
16.7% 
2.8% 
Sex (n = 36) 
Male 
Female 
16 
20 
44.4% 
55.6% 
BF (n = 24) 
Yes 
No 
10 
14 
41.7% 
58.3% 
Living with Mother  (Currently) (n = 34) 
Yes 33 97.1% 
No 1 2.9% 
Baseline Characteristics of the Maternal Factors 
Education Level (n = 34) 
Primary & Below 
Secondary&Above 
21 
13 
61.8% 
38.2 % 
Ethnicity (n = 34) 
Bantu 
Nilotes 
Cushites 
22 
11 
1 
64.7% 
32.4% 
2.9% 
 
We enrolled thirty six black African children into the study between March 2007 and 
March 2008. They were of median age 10.9 months ranging from 4.1 to 30.6 months and 
55.6% were female. Sixty two percent of the mothers had a maximum of primary level 
education and 38% had secondary and above qualifications.  Forty two percent of the 
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children were currently breastfeeding. Ninety seven percent were currently living with 
their birth mothers. Mothers were from various ethnic groupings with 65% Bantu, 32% 
Nilotes and 3 % cushites.  
 
4.2 BIRTH CHARACTERISTICS OF STUDY POPULATION 
 
Table 4.0-2: Birth Characteristics Of Study Population (from initial assessment) 
Characteristic Frequency or Median Percentage or Range 
PMTCT (n = 34) 
Yes 12 35.3% 
No 22 64.7% 
Birth History (n = 34) 
SVD 
C/S 
29 
5 
85.3% 
14.7% 
 
The majority (85.3%) were born through normal vaginal delivery. All were HAART 
naïve, though 35.3 % of mother / child pair were exposed to nevirapine PMTCT around 
birth.  
 
4.3 CLINICAL CHARACTERISTICS OF STUDY 
POPULATION 
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World Health Organization disease stages in these children were II in 5.9%, III in 32.4% 
and IV in 61.8%. Median CD4 counts were 715.5. Forty three percent had hemoglobin 
levels less than 10g/dl. 
 
Table 4.0-3: Clinical characteristics of study population (from initial assessment) 
Characteristic Frequency or Median Percentage or Range 
Initial Staging (n = 36) 
II 
III 
IV 
4 
11 
21 
5.9% 
32.4% 
61.8% 
HB g/dl (n = 20)  
≤ 10 
> 10 
8.5 
11.1 
4.3  9.3 
10.2  17.2 
CD4 count (n = 24) Mean 860 SD 621 
Absolute count 715.5 2.0  2,416 
CD4% (n = 24)  
Mild 
Advanced 
Severe Immunosuppresed 
1 
4 
19 
4.2% 
16.7% 
79.2% 
 
According to 2006 WHO HIV immunosuppression by CD4% classification, 4.2% had 
mild immunosuppression, severe immunosuppression 16.7% and advanced 
immunosuppression 79.2%. 
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 4.4 PREVALENCE OF NEURODEVELOPMENT DELAY 
AMONG A COHORT OF KENYAN CHILDREN INFECTED 
WITH HIV 
 
Table 4.0-4: Prevalence Rates For ND Delay Among HIV Infected Children (From 
initial assessment) 
 
Type of ND delay N Frequency Percentage 
Any delay 36 32 88.9% 
Cognitive delay 36 22 61.2% 
Language delay 36 24 66.6% 
Motor delay 36 30 83.3% 
SES delay 33 12 36.4% 
Adaptive delay 33 20 60.6% 
 
Twenty nine children of the thirty six had at least one extremely low qualitative 
assessment (composite score development quotient of 69 and less) in at least one ND 
parameter. Two others had at least two ND parameter assessments that fell in the 
borderline group (composite score of 70 to 79) and one other at least one.  As a result 
only four out of the cohort of 36 children with HIV did not have any type of 
neurodevelopment delay in any one development constructs assessed. This put the overall 
prevalence rate at 88.9%. Motor delay was the highest specific type of neurodevelopment 
delay followed by language, cognitive and adaptive delay respectively. 
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4.5: SPECTRUM OF ND DELAY AMONG A COHORT 
OF KENYAN CHILDREN INFECTED WITH HIV 
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Figure 4.0-1: ND composite scores of study population (From initial assessment). 
 
The full spectrum of neurodevelopment function was observed in the study population, 
ranging from extremely low qualitative description to very superior. All aspects of ND 
delay as assessed by the BSID III as noted by the columns showing composite scores of 
under 69 and 70  79 was also present. (See figure 4.1 above). 
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Table 4.0-5: Spectrum of ND Delay: Median Bayley Composite Score Summary 
(From initial assessment) 
Parameter N Median score IQR Score qualitative description 
Cognitive 36 65 5588.75 Extremely low 
Language 36 72.5 5989 Borderline 
Motor 36 61.0 49.7578.25 Extremely low 
SES 33 90 70-95 Average 
Adaptive 33 76 58-95.5 Borderline 
 
Median motor and cognitive scores were in the extremely low ND zone, language and 
adaptive scores fell in the borderline ND range. SES median scores qualitative 
description was normal (table 4.5). Using the definition of ND delay represented in table 
3.1, median scores that are delayed are those of cognitive, language motor and adaptive 
parameters. 
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4.6  SEVERITY OF NEURODEVELOPMENT DELAY AMONG 
A COHORT OF KENYAN CHILDREN INFECTED WITH HIV 
Table 4-0-6: Severity of ND Delay: Qualitative Bayley Composite Score 
Distribution. (From initial assessment) 
ND Classification Cognitive 
Freq (%) 
Language 
Freq (%) 
Motor 
Freq (%) 
SES 
Freq (%) 
Adaptive 
Freq (%) 
NEURODEVELOPMENTAL DELAYED  
Extremely low 20 (55.6) 16 (44.4) 25 (69.4) 10 (30.3) 16 (48.5) 
Borderline 2 (5.6) 8 (22.2) 5 (13.9) 2 (6.1) 4 (12.1) 
Sub Total 22 (61.1) 24 (66.7) 30 (83.3) 12 (36.4) 20 (60.6) 
NOT NEURODEVELOPMENTALY DELAYED 
Low average 6 (16.7) 6 (16.7) 3 (8.3) 4 (12.1) 4 (12.1) 
Average 5 (13.9) 5 (13.9) 2 (5.6) 15 (45.5) 8 (24.2) 
Above average 3 (8.3) 1 (2.8) 1 (2.8) 2 (6) 1 (3) 
Sub Total 14 (38.9) 12 (33.3) 6 (16.7) 21 (63.6) 13 (39.4) 
Total 36 (100) 36 (100) 36 (100) 33 (100) 33 (100) 
* SES: Socio-emotional status 
*GAD: General Adaptive Behavior 
 
Motor delay is severe with most of the children scoring in the extremely low qualitative 
description range. The same point is replicated in the cognitive, language and general 
adaptive scores. Social emotional mode lies in the average qualitative description range. 
This table and the prevalence data calculated earlier on summarises the fact that of the 
neurodevelopment delay that occurs most fall in the extremely low qualitative category 
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especially in the cognitive, language, motor and general adaptive constructs. These are 
the most affected of the ND parameters in the Kenyan child with HIV.  
 
4.7 FACTORS ASSOCIATED WITH NEURODEVELOPMENT 
DELAY AMONG A COHORT OF KENYAN CHILDREN 
INFECTED WITH HIV 
 
Fischers exact and Pearsons chi square statistics were done to determine factors 
associated with ND delay in this cohort. The definition of ND was that fell in the 
borderline and extremely low group (See table 3.1 in case definitions). 
 
Fischers statistics were used in data cells that had less than five children in this analysis. 
Those that did not have any with less than five, Pearsons chi square statistics were used. 
 
Risk factors used in data analysis in this chapter are; age, sex, mode of delivery, PMTCT, 
maternal education, initial HIV WHO staging, initial CD4% and current infant breast 
feeding. 
 45 
Table 4-0-7: Factors Associated With Any Delayed ND Score (From initial 
assessment) 
Any ND Delay 2  p-value Risk Factors 
Yes, n (%) No, n (%)   
Infant Age 
 ≥ 18 
 < 18 
 
11 (34.4) 
21 (65.6) 
 
- 
3 (100.0) 
 
0.33 
 
0.220 
Sex 
 Female  
 Male 
 
18 (56.3) 
14 (43.8) 
 
1 (33.3) 
2 (66.7) 
 
0.02 
 
0.461 
Mode of Delivery 
 SVD 
 C/S 
 
24 (82.8) 
5 (17.2) 
 
2 (100.) 
- 
 
0.12 
 
0.434 
PMTCT 
 Yes 
 No 
 
10 (34.5) 
19 (65.5) 
 
1 (33.3) 
2 (66.7) 
0.36  
0.968 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
16 (55.2) 
13 (44.8) 
 
3 (100.0) 
- 
 
0.79 
 
0.132 
Initial Staging 
 ≤ II 
 ≥ III 
 
27 (93.1) 
2 (6.9) 
 
3 (100.0) 
- 
 
0.16 
 
0.639 
CD4% 
 Other  
 Severe 
 
18 (81.8) 
4 (18.2) 
 
1 (50.0) 
1 (50.0) 
 
0.02 
 
0.289 
Infant BF 
 Yes 
 No 
 
6 (20.7) 
23 (79.3) 
 
3 (100.0) 
- 
 
4.99 
 
0.004 
*Fischers exact chi square statistics 
 
This analysis  shows that not  breast feeding was associated with a higher risk of having 
any ND delay in any one development parameter as assessed by the BSID III (100% of 
those who did not breastfeed developed delay as opposed to 67.7% of those who did, p 
value of 0.004).  
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Table 4.0-8: Factors Associated With ND delayed Cognitive Scores (From initial 
assessment 
Cognitive delay  p-value 
Risk Factors Yes, n (%) No, n (%) 2   
Age in months 
 ≥ 18 
 < 18 
 
10 (45.5) 
12 (54.5) 
 
1 (7.1) 
13 (92.9) 
4.25  
0.015 
Sex 
 Female  
 Male 
 
12 (54.5) 
10 (45.5) 
 
8 (57.1) 
6 (42.9) 
0.04  
0.577 
Mode of Delivery 
 SVD 
 C/S 
 
18 (90.0) 
2 (10.0) 
 
10 (76.9) 
3 (23.1) 
0.28  
0.306 
PMTCT 
 Yes 
 No 
 
5 (25.0) 
15 (75.0) 
 
6 (46.2) 
7 (53.8) 
0.78  
0.208 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
8 (40.0) 
12 (60.0) 
 
12(92.3) 
1 (7.7) 
6.97  
0.003 
Initial Staging 
 I or II 
 III or IV 
 
1 (5.0) 
19 (90.9) 
 
1 (7.7) 
12 (92.3) 
0.18  
0.751 
Immunosuppression by CD4% 
 Severe 
 Non  severe 
 
14 (87.5) 
2 (12.5) 
 
5 (62.5) 
3 (37.5) 
0.78  
0.155 
BF 
 Yes 
 No 
 
4 (20.0) 
16 (80.0) 
 
5 (38.5) 
8 (61.5) 
0.58  
0.245 
*Fischers exact chi square statistics 
 
Table 4.8 shows a child who is 18 months and above is more likely to have scores that 
fall in the extremely low cognitive delay range than one who is under 18 months (90.9% 
versus 48.0%, p-value 0.015). Children from mothers educated to a maximum of primary 
level are less likely to get extremely low cognitive delay in this cohort than those whose 
mothers had a higher education (40% versus 92.3%, p-value 0.003).  
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Table 4. 0-9: Factors Associated With ND delayed Language Scores (From initial 
assessment) 
Language delay  p-value 
Risk Factors Yes, n (%) No, n (%) 2   
Age in months 
 ≥ 18 
 < 18 
 
11 (45.8) 
13 (54.2) 
 
- 
12 (100.0) 
 
 
5.91 
 
0.005 
Sex 
 Female  
 Male 
 
13 (54.2) 
11 (45.8) 
 
7 (58.3) 
5 (41.7) 
 
 
0.01 
 
0.813 
Mode of Delivery 
 SVD 
 C/S 
 
20 (90.9) 
2 (9.1) 
 
8 (72.7) 
3 (27.3) 
 
 
0.74 
 
0.170 
PMTCT 
 Yes 
 No 
 
6 (27.3) 
16 (72.7) 
 
5 (45.5) 
6 (54.5) 
 
 
0.43 
 
0.296 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
12 (54.5) 
10 (45.5) 
 
8 (72.7) 
3 (27.3) 
 
 
0.40 
 
0.314 
Initial Staging 
 III or IV 
 I or II 
 
21 (95.5)  
1 (4.5)  
 
10 (90.9)  
1 (9.1)  
 
 
0.07 
 
0.606 
Immunosuppression by CD4% 
 Severe 
 Non  severe 
 
15 (88.2) 
2 (11.8) 
 
4 (57.1) 
3 (42.9) 
 
 
1.33 
 
0.088 
BF 
 Yes 
 No 
 
5 (22.7) 
17 (77.3) 
 
4 (36.4) 
7 (63.6) 
 
 
0.17 
 
0.407 
*Fischers exact chi square statistics 
 
Being over 18 months of age is a risk factor for developing language ND  delay in this 
cohort ( 100% versus 52%, p-value 0.005).  
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Table 4.0-10: Factors associated with ND delayed motor scores (From initial 
assessment) 
Motor delay 2  p-value Risk Factors 
Yes, n (%) No, n (%)   
Age in months 
 ≥ 18 
 < 18 
 
10 (33.3) 
20 (66.7) 
 
1 (16.7) 
5 (83.3) 
0.10  
0.418 
Sex 
 Female  
 Male 
 
16 (53.3) 
14 (46.7) 
 
4 (66.7) 
2 (33.3) 
0.02  
0.549 
Mode of Delivery 
 SVD 
 C/S 
 
22 (81.5) 
5 (18.5) 
 
6 (100.0) 
- 
0.27  
0.252 
PMTCT 
 Yes 
 No 
 
9 (33.3) 
18 (66.7) 
 
2 (33.3) 
4 (66.7) 
0.23  
1.000 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
16 (59.3) 
11 (40.7) 
 
4 (66.7) 
2 (33.3) 
0.02  
0.737 
Initial Staging 
 III or IV 
 I or II 
 
26 (96.3)  
1 (3.7) 
 
5 (83.3)  
1 (16.7) 
0.07  
0.229 
Immunosuppression by CD4% 
 Severe 
 Non  severe 
 
17 (85.0) 
3 (15.0) 
 
2 (50.0) 
2 (50.0) 
0.81  
0.116 
BF 
 Yes 
 No 
 
6 (22.2) 
21 (77.8) 
 
3 (50.0) 
3 (50.0) 
0.77  
0.167 
*Fischers exact chi square statistics 
 
There were no factors in this analysis that showed any association with motor delay 
despite the fact that it is the most prevalent type in this cohort. 
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Table 4.0-11: Factors associated with ND delayed SES scores (From initial  
assessment) 
SES delay 2  p-value Risk Factors 
Yes, n (%) No, n (%)   
Age in months 
 ≥ 18  
 < 18 
 
7 (58.3) 
5 (41.7) 
 
3 (14.3) 
18 (85.7) 
 
 
5.08 
 
0.008 
Sex 
 Female  
 Male 
 
7 (58.3) 
5 (41.7) 
 
11 (52.4) 
10 (47.6) 
 
 
0.00 
 
0.741 
Mode of Delivery 
 SVD 
 C/S 
 
10 (90.9) 
1 (9.1) 
 
17 (85.0) 
3 (15.0) 
 
 
0.01 
 
0.639 
PMTCT 
 Yes 
 No 
 
4 (36.4) 
7 (63.6) 
 
7 (35.0) 
13 (65.0) 
 
 
0.10 
 
0.939 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
6 (54.5) 
5 (45.5) 
 
13 (65.0) 
7 (35.0) 
 
 
0.03 
 
0.567 
Initial Staging 
 III or IV 
 I or II 
 
10 (90.9) 
1 (9.1) 
 
19 (95.5) 
1 (5.0) 
 
 
0.10 
 
0.657 
Immunosuppression by CD4% 
 Severe 
 Non  severe 
 
6 (75.0) 
2 (25.0) 
 
12 (80.0) 
3 (20.0) 
    
 
   0.06 
 
0.782 
BF 
 Yes 
 No 
 
2 (18.2) 
9 (81.8) 
 
7 (35.0) 
13 (65.0) 
 
 
0.33 
 
0.324 
*Fischers exact chi square statistics 
*SES Socioemotional status 
 
Age, being older than 18 months once again is significantly associated with social 
emotional delay (70.0% versus 21.7%, p-value 0.008). None of the other risk factors 
seem to statistically increase the chances of a child having a lower socio-emotional score. 
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Table 4.0-12: Factors associated with ND delayed GAD scores (From initial 
assessment) 
GAD delay  p-value 
Risk Factors Yes, n (%) No, n (%) 2   
Age in months 
 ≥ 18 
 < 18 
 
9 (44.5) 
11 (55.0) 
 
- 
13 (100.0) 
5.93  
0.005 
Sex 
 Female  
 Male 
 
11 (55.0) 
9 (45.0) 
 
7 (53.8) 
6 (46.2) 
0.09  
0.948 
Mode of Delivery 
 SVD 
 C/S 
 
16 (88.9) 
2 (11.1) 
 
11 (84.6) 
2 (15.4) 
0.04  
0.726 
PMTCT 
 Yes 
 No 
 
5 (27.8) 
13 (72.2) 
 
6 (46.2) 
7 (53.8) 
0.46  
0.291 
Mother Education 
 Primary & Below 
 Secondary & Above 
 
11 (61.1) 
7 (38.9) 
 
9 (69.2) 
4 (30.8) 
0.01  
0.641 
Initial Staging 
 III or IV 
 I or II 
 
18 (100.0) 
- 
 
12 (92.3) 
1 (7.7) 
0.03  
0.232 
Immunosuppression by CD4% 
 Severe 
 Non  severe 
 
12 (85.7) 
2 (14.3) 
 
6 (75.0) 
2 (25.0) 
0.00  
0.531 
BF 
 Yes 
 No 
 
5 (27.8) 
13 (72.2) 
 
4 (30.8) 
9 (69.2) 
0.05  
0.856 
*Fischers exact chi square statistics 
*GAD General Adaptive Behaviour 
 
Children older than or equal to 18months are significantly more likely to have general 
adaptive delay (100% versus 45.8%, P-value 0.005). None of the other risk factors seem 
to have a statistically significant role in this cohort. 
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4.8 COMPOSITE SCORES AFTER AT LEAST 6 MONTHS OF 
HAART  
 
Only 12 children out of the 36 completed the follow up after at least six months of 
HAART. 
 
Table 4.0-13: Trend In Composite Score Over The Study Period (N = 12) (From 
both initial and final assessment) 
 
    
Summary Scaled Score Mean (SE)  95% CI         P-value 
 
Cognitive  
Initial     69.58 (±486)  (-15.40 to -2.10) 0.015 
≥ 6 months of HAART  78.33 (±4.23)  
 
Language 
Initial     67.00 (±3.37)  (-19.20 to -4.14) 0.006 
≥ 6 months of HAART 78.37 (±2.80)  
 
Motor 
Initial     62.75 (±3.85)  (-13.58 to 3.08) 0.193 
≥ 6 months of HAART 68.00 (±3.68)  
 
Socio-emotional  
Initial     81.25 (±6.03)  (-34.67 to -2.00) 0.031 
≥ 6 months of HAART 99.58 (±5.13)  
 
General Adaptive 
Initial     67.25 (±5.93)  (-16.35 to 6.69) 0.376 
≥ 6 months of HAART 72.08 (±4.33)  
 
 
A paired t test comparing the means of the 12 patients who had results at baseline and 
after at least 6 months of ART realized an improvement in cognitive, language and socio-
emotional scores. It is however important to note that apart from SES, all other ND 
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parameters scores after at least six months of HAART fell in the ND delay range (See 
table 3.1).  
 
Though the power of this test is limited, it is in keeping with other studies who realized 
similar results as discussed in the following chapter. 
 
Table 4.0-14: Comparison between demographic characteristics of those who did 
and did not complete study (From initial / baseline assessment visit) 
Study completion status P-value 
Factors Completed Lost to follow-up   
  n % n %   
Age: n = 36   
≤ 5 - - 3 12.5 
6  10 3 25 10 41.7 
11  15 2 16.7 6 25 
16  20 1 16.7 1 4.2 
21  25 2 16.7 1 4.2 
25 +  4 33.3 3 12.5 
0.121 
Sex: n = 36   
Male 7 58.3 9 37.5 
Female 5 41.7 15 62.5 
0.406 
Birth History: n = 34   
SVD 10 83.3 19 86.4 
C/S 2 16.7 3 13.3 
1 
PMTCT : n = 34   
Yes 3 25 9 40.9 
No 9 75 13 59.1 
0.465 
Initial Staging: n = 34   
II 1 8.3 1 4.5 
III  5 41.7 6 27.3 
IV 6 50 15 68.2 
0.576 
 
A paired t test comparing demographic characteristics of those who failed to and those 
who completed the study was done (table 4.14 above). It shows that there is no difference 
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in the age, sex, birth history, PMTCT and initial staging characteristics of the two 
populations. One can then assume that the results of those lost to follow - up are similar 
to those who completed the study.  
 
4.9 MORTALITY 
Male ,2 (28.6%)
Female,5 (71.4%)
 
Figure 4.2: Mortality Distribution By Sex (N = 7) 
 
 
Of the children who did not finish the study, seven are known to have died. Of these most 
were in WHO stage four (71.4%).  
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Table 4.15: Neurodevelopmental Delay And Mortality (from initial assessment) 
Dead p-value 
Yes No Developmental Delay 
N % N % 
 
Cognitive 6 27.3 16 72.7 0.137 
Language 5 20.8 19 79.2 0.766 
Motor 6  20.0 24 80.0 0.851 
SES 1 8.3 11 91.7 0.171 
GAD 3 15 17 85 0.279 
*Fischers exact chi square statistics 
*SES Socioemotional status 
*GAD General Adaptive Behaviour 
 
 This table shows of the 22 children who had cognitive delay in the initial assessment, as 
defined as extremely low and borderline cognitive score (see table 4.6) six died.  
Likewise using table 4.6 in language five out of the 24 with language delay died; Motor 
six out of the 30 with motor delay died; SES one out of the 12 with delay in this construct 
died; and three out of 20 with the ND delay died in adaptation.  
 
There is however no association between mortality and  any of the ND constructs 
assessed. These numbers are too low to make any conclusion. 
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CHAPTER FIVE: DISCUSSION OF RESULTS 
 
This protocols research question sought to unravel the prevalence, spectrum and severity 
of the Kenyan HIV infected childs neurodevelopment delay and factors that affect it. A 
standardized tool the BSID III third edition was employed.   
 
5.1 PREVALENCE OF NEURODEVELOPMENT DELAY 
AMONG A COHORT OF KENYAN CHILDREN INFECTED 
WITH HIV 
 
Of the 36 children in this cohort only four did not need any intervention for 
neurodevelopment delay (Table 4.4) according to the AAMR (see chapter 2.3). This is a 
very high overall prevalence of 88.9%. Motor delay is especially prevalent 83.3%, while 
cognitive, language and adaptive delay present in this cohort were 61.2%, 66.6% and 
60.6% respectively (Table 4.4).  
 
Other neurodevelopment studies in Africa have also realized high prevalence rates. 
Potterton in South Africa  using BSID II, had a prevalence rate of 78% cognitive delay 
and 87% motor delay (Potterton, 2006). Most studies however use a development 
quotient two SDs below the mean as a definition of ND delay in accordance with the 
APA.  Figures falling in the above definition are those that are in the qualitative 
description of extremely low (table 4.6).  Extremely low percentage rates were 55.6%, 
44.4%, 69.4%, 30.3% and 48.5% for cognitive, language, motor, SES, adaptive ND 
parameters respectively.  
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A study in DRC using BSID II had severe ND delay prevalence rates of 60% cognitive 
and 28.6% motor (Van Rie et al 2008). These rates changed to 91% cognitive and 82% 
motor delays in their lower age range, 18 to 29 months (Van Rie et al, 2008) which is part 
of this Kenyan cohorts age range.  
 
A meta analysis reported by Van Rie et al 2006, had prevalence rates ranging from under 
8% to over  60 % in motor, cognitive and speech delay. In this systemic review Rwanda 
with a small cohort and simple screening tools reported prevalence rates of 15% to 40% 
of mainly gross motor delays. Uganda studying HIV infected children by 12 months had 
rates of 30% and 26% of motor and cognitive delay respectively (Van Rie et al 2006).  
 
5.2 SPECTRUM OF NEURODEVELOPMENT DELAY 
AMONG A COHORT OF KENYAN CHILDREN INFECTED 
WITH HIV  
 
All aspects of ND delay as measured by BSID III was realized in this cohort. Table 4.5 
show that motor, cognitive, language and adaptive delay are more likely to occur as 
evidenced by their median scores. One has to plan to manage these delays as well as the 
primary condition of HIV. It is clear that a holistic management approach that addresses 
all these abnormalities is mandatory as one handles a child living with HIV (Van Rie et 
al, 2006; Forster et al, 2006). 
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5.3 SEVERITY OF NEURODEVELOPMENT DELAY 
AMONG A COHORT OF KENYAN CHILDREN INFECTED 
WITH HIV 
 
These results also point out that most of those with neurodevelopment delay had the 
severest of the malady. Many of their scores fell in the extremely low qualitative range at 
least in the motor, cognitive, language and adaptive parameters (Table 4.6). This is the 
group with a development quotient of 69 and less and falls in the neuropsychological 
profiling that places them at the highest risk for later disease progression (Pearson et al 
2000). 
 
Globally several studies have reported lower neuropsychological scores in  HIV infected 
children (Knight et al, 2008; Forster et al, 2006 ; Lindsey et al, 2007) and it has been 
proven that these assessments have useful disease progression predictive value and 
monitoring information (Pearson et al 2000). While the Bayley III was not standardized 
for Kenya purposeful enabling easy comparison of these results with other global studies, 
this study shows that there is a possibility of increased holistic follow up of HIV children 
in Kenya if neurodevelopment assessments are incorporated into the standard of care in 
children  represented by this cohort. 
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5.4 FACTORS AFFECTING NEURODEVELOPMENT DELAY 
AMONG A COHORT OF KENYAN CHILDREN INFECTED 
WITH HIV  
 
This study also looked as some risk factors and their effect on ND of children infected 
with HIV in Kenya. Fischers exact chi square analysis per each category of  extremely 
low ND scores were done. This is to enable favourable comparisons with other studies 
who analyse using these scores. 
 
5.4.1 FACTORS AFFECTING OVERALL DELAY PICTURE 
 
Table 4.7 shows breastfeeding is protective against developing any delay in any one ND 
parameter (p value 0.004). Breast feeding has been linked to low mortality in HIV 
infected children from resource poor countries who lack the resources to buy formula in 
the first six months of life (ANECA, 2006; Nduati et al, 2001; Mbori Ngacha et al, 2001). 
It is also an important MTCT route (ANECA, 2006; Nduati et al, 2001; Mbori Ngacha et 
al, 2001). To balance the two previous points HIV mothers without alternative food have 
been advised to exclusively breastfeed for the first six months of life and then wean 
abruptly (ANECA, 2006). 
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5.4.2 FACTORS AFFECTING SPECIFIC DELAY PARAMETERS 
 
5.4.2.1 AGE 
 
It is interesting to note that the older child (18 months or more in age) was more at risk of 
getting  cognitve, language, SES and adaptive delay (tables 4.8, 4.9, 4.11 and 4.12). 
Possible explanations lie in the fact that this being a HAART naïve population, we 
captured most of the ones whose disease progression was at an advanced stage with most 
of the rapid progressors having died in their infancy (Obimbo et al, 2004). These children 
are also more at risk of being affected by socio-enviromental factors. Van Rie et al 
reports results of a study in Tanzania whose older children had lower Bayley scores. 
These are more vulnerable to the combined effect of poverty, HIV illness and family 
stress on neurodevelopment (Van Rie et al 2006, Van Rie et al 2008). Many other studies 
however report the reverse with younger children being at a higher risk of ND delay. 
Most of their young children fall in the 18 to 24 months category and is in keeping with 
our older population of over 18 months.  
 
5.4.2.2 MATERNAL EDUCATION 
 
Maternal education affects baseline cognitive scores with those of lower education  better 
than their counterparts, tables 4.8 (p = 0.005). This is unlike the systemic review results 
of Van Rie et al 2006. The poorly educated mothers in this cohort have no careers, are 
stay at home mums therefore have a lot of time and love to invest in their children. These 
children benefit from a secure attachment and the most of the available mental 
stimulation from their mothers hence the better cognitve scores. One can postulate that 
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presence of the mother to the child overrides a higher maternal education and socio-
economic status in the overall cognitive development of the child. 
 
In Kenya the more educated counterparts in this cohort fall in the lower middle class and 
have careers that take up most of their day. House helps with lower socio-economic and 
educational levels are employed to baby sit and perform household chores. There is 
usually a high turnover of these house helps, additional household chores reduce time 
spent with the children and any mental stimulation from them is definitely of a lower 
quality than that from the mother had she been more available. 
 
5.4.2.3 IMMUNOSUPPRESSION BY CD4% 
 
Immuno-suppression by CD4%  did not realize any significant p values in this cohort. 
Forster et al 2006 concluded that the worse the immunological compromise the more the 
abnormal neurological functioning. Other studies have realized definite association with 
immunosuppression  as defined by higher viral loads and neurodevelopment delay 
(Chiriboga et al, 2005; Jeremy et al, 2005).  
 
5.4.2.4 BREAST FEEDING 
 
Breast feeding was associated with better outcome against having ND delay in any one 
ND parameter as assessed by BSID III. In this population the fact that breast milk is free, 
nutritionally complete and not expensive either to acquire or maintain is important. It also 
ensures bonding and a secure attachment for the child. This ensures adequate stimulation 
which improves all aspects of ND functioning.  Formula is expensive and all those 
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children who were not breast fed may not have had access to nutritional optimum 
alternatives. They also would lack the special mother child bonding and are at risk of 
attachment disorders. This may explain why 100% of them had ND delay in any one 
parameter as assessed by the BSID III. 
 
5.4.2.5 TREATMENT 
 
All these children received medical treatment that included HAART. Involvement of the 
rehabilitational sciences was minimal if any. Some services like speech therapy are not 
developed.  Physio and occupational therapy services which are available in KNH 
involve frequent hospital visits. This means many bus fares making the financial 
obligation out of reach for most of these mothers. Being out of the home several days a 
week or month may also not be feasible for these mothers. These children were followed 
up for a period of at least six months post HAART.  Loss to follow up was massive with 
only 12 out of the original 36 finishing the study period. Table 4.15 however shows there 
was no difference in the baseline age, HIV stage, sex, PMTCT status and birth history of 
the population who completed the study and those who did not.  
  
After at least six months of Art, ND constructs that improved were cognition, language 
and SES (table 4.14). Improvement is limited in keeping with results of other studies 
(Potterton 2006; Lindsey et al, 2007; Forster et al, 2007;).  HAART did not improve the 
motor delay which was the most severe and prevalent.  
 
This data is of clinical significance because while there was improvement in the 
cognitive, language and general adaptive mean composite scores they still fell in the 
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borderline qualitative distribution. These means these parameters were still delayed (see 
chapter 2. on AAMR definition of ND). Extra therapeutic measures apart from HAART 
are needed to adequately address these delays. Other studies with similar results include 
Forster et al, 2007 who followed up 62 children under three years using BSID II. A 
systematic review by Van Rie et as, 2006 validated these findings. Potterton realized that 
a home developmental stimulation program added to HAART had a bigger ND function  
improvement over one years follow up (Potterton, 2006). The general adaptive delay was 
also not improved by HAART. 
 
 Further research is needed to validate this data statistically in the Kenyan population but 
clinicians can review the management of these aspects of neurodevelopment delay in the 
HIV infected child. 
 
5.5 LIMITATIONS OF STUDY 
 
5.5.1 STUDY DESIGN 
 
 
This was a prospective cohort study. The study heavily depended on the follow up of 
recruited study subjects. The study design therefore exposed research to loss of follow up 
which affected this particular study. 
 
5.5.2 VARIABLES MEASURED 
 
The Bailey Scales are a standardized tool whose interpretation is dependent on the 
uniformity of their applications. This is a limitation as it was not possible to adapt them to 
the Kenyan population without compromising on the data collected. The variables 
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measured were authentic especially when compared with results from other studies 
chapter 5.1, 5.2 and 5.3.  
 
5.5.3 LOSS TO FOLLOW UP 
 
One of the major limitation of this study was the political environment in which the study 
period fell. The cohort was drawn from the KNH, CCC patronized mainly by patients at 
the lower end of the socioeconomic spectrum. These people live in the slum and estates 
bordering them. Slum populations are hetero ethnic but each has one particular dominant 
tribe. Kenyan politics in the year 2007 divided the country along ethnic lines and slum 
population migration was taking place even before the vote casting day. This complicated 
the follow up of patients a fact made worse by the post election violence which resulted 
in many internally displaced persons. As a result only 12 patients out of the initial 36 
were able to have follow-ups of at least 6 months after ART initiation, despite all efforts 
to follow them up. 
 
 
5.6 RECOMENDATIONS. 
 
5.6.1 CLINICAL RECOMMENDATIONS 
 
Table 4.5 shows that in this cohort 89% of these children need the services of an early 
intervention center. Children respond to interventions carefully directed to specific or 
pervasive neurocognitive dysfunction irrespective of aetiology (Willen, 2006). 
Specialised rehabilitational services are important in HIV as these children are now 
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surviving longer and will need an optimal ND functioning to integrate and contribute to 
society (Forster et al, 2007). Rehabilitaion optimizes performance breaking the vicious 
cycle of poverty so prevalent in HIV infected children (Van Rie et al, 2006) especially in 
Sub Saharan Africa.  
 
Kenya, like many sub Saharan countries have not made the strides in rehabilitational 
sciences so evident in the West. This makes these services either not present or under 
utilized even in other neurodevelopmental pathologies not necessarily HIV. Clinicians in 
Kenya have to use more of the rehabilitational sciences and make use of neurocognitive 
profiling to monitor progress of the HIV infected childs ND status with time. 
 
5.6.2 RESEARCH RECOMMENDATIONS 
 
The mainstay of HIV treatment in Kenya is HAART. Though the loss to follow up was 
colossal and data from the 12 children who at least completed six months of follow up 
(table 4.14) has limited statistical power it is in keeping with results from many other 
studies (Chiriboga et al, 2005; Jeremy et al, 2005; Van Rie et al, 2006; Potterton,2006; 
Lindsey et al, 2007) that show that HAART does not adequately address the 
neurodevelopment abnormalities prevalent in children infected with HIV. 
 
Further research needs to be done on the effect of HAART on the ND of  Kenyan child 
infected with HIV. 
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5.7 CONCLUSION 
 
5.7.1 PREVALENCE OF ND DELAY AMONG A COHORT OF 
KENYAN CHILDREN INFECTED WITH HIV 
  
ND delay in this cohort of Kenyan children with HIV is very prevalent. Those who had 
ND delay in any one parameter as assessed by the BSID III were 88.9%. Motor delay had 
the highest specific prevalence of 83.3% followed by language delay at 66.6%, cognitive 
delay at 61.2%, adaptive delay at 60.6% and SES delay at 36.4% respectively. 
 
5.7.2 SPECTRUM OF ND DELAY AMONG A COHORT OF KENYAN 
CHILDREN INFECTED WITH HIV 
 
The spectrum of ND delay in this cohort of Kenyan children infected with HIV, 
encompasses all aspects of ND delay as measured by the BSID III. These are cognitive, 
language, motor, SES and general adaptive delays. 
 
5.7.3 SEVERITY OF ND DELAY AMONG A COHORT OF KENYAN 
CHILDREN INFECTED WITH HIV 
 
The severity of ND delay this cohort of Kenyan children infected with HIV is high with 
most of those with neurodevelopment compromise falling in the extremely low as 
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opposed to the borderline group (see table 4.4). Those with severe delay (extremely low) 
as opposed to mild (borderline) ND delay were 69.4% versus 13.9% for motor delay; 
55.6% versus 5.6% for cognitive delay, 44.4% versus 22.2% for language delay; 48.5% 
versus 12.1% for adaptive delay and 30.3% versus 6.1% for SES delay. 
 
5.7.4 FACTORS ASSOCIATED WITH ND DELAY AMONG A COHORT 
OF KENYAN CHILDREN INFECTED WITH HIV  
 
Important factors associated with ND delay this cohort of Kenyan children infected with 
HIV were breast feeding, age and maternal education. Breast feeding was associated with 
protection from developing ND delay in any one parameter as assessed by the BSID. 
Being older than 18 months was associated with worse cognitive, language, SES and 
adaptive outcomes. Lower maternal education was associated with better cognitive results 
in this cohort. 
 
5.7.5 TREATMENT AND ND DELAY AMONG A COHORT OF 
KENYAN CHILDREN INFECTED WITH HIV  
 
Data concerning treatment in this cohort of Kenyan children infected with HIV was 
affected by the loss to follow up. For those study subjects with a BSID III assessment 
after at least six months of HAART, their ND outcome showed that this treatment alone 
was not sufficient to make it normal. This is an interesting hypothesis that can be used for 
future research. 
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Appendix I: Ethics Approval University of Witwatersrand 
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Appendix II: Ethics Approval University of Nairobi 
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Appendix III: WHO 2006 immunological classification for 
established HIV infection 
 
Age-related CD4 values 
 
HIV-associated 
immunodeficiency 
 <11 
months 
(%CD4+) 
 
12 - 35 
months 
(%CD4+) 
 
36  59 
months 
(%CD4+) 
 
>5 years 
(absolute 
number 
per mm3 or 
%CD4+) 
 
None or not significant  
 
>35 >30 >25 >500 
Mild 
 
30 -35 25  30 20  25 350  499 
Advanced 
 
25  29 20  24 15  19 200  349 
Severe 
 
<25 <20 <15 <200 or <15% 
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Appendix  IV: Demography form  
 
Study number;. Age;. Date of birth;. Tribe; Telephone number;  
Birth order; Birth history; svd.. c/s.. Pmtct;yes.. no.. Live with birth mother;yes.. no..  
Main systemic complaints. 
Breast feeding currently; yes  no  stopping date& age  
Food supplements;      yes  no  type 
Last evening meal contents:.. 
Previous hospital admissions; give dates & length of hospital stay. 
Siblings; number  ages   on arvs 
Mothers education level 
 71 
Appendix V: Information Sheet 
 
My name is Dr Mary Mupa Madumadu Kigira. Current  research has shown that HIV  
treatment improves the development and working of childrens nervous systems. I am 
carrying out a study to measure this improvement in Kenyan children. 
I will use a specialized test known as the Bayley Scales of Infant Development to 
measure this. The test is harmless, painless and will take about an hour to perform. If you 
allow your child to participate in this study, this test will be performed on your child free 
of charge. The results of your childs test and their meaning will be explained to you. I 
will also study your childs medical records for research purposes only and will maintain 
strict confidentiality.  
It is not a must to include your child and you are free to withdraw your child from this 
study whenever you feel like. Whether you choose to participate or not will not affect the 
quality of care your child will get at the clinic. If you have any questions feel free to call 
me at 0722 786 220. If you agree in your childs participation kindly sign below. 
SIGNED     DATE 
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Appendix VI: Consent form 
 
I     the mother/ father/ legal guardian of      
Agree to let Dr Mary Mupa Madumadu Kigira carry out the Bayley Scales of Infant 
Development on my child. I also allow her to study my childs medical records for 
research purposes. The study has been explained to me and I fully understand its 
purposes and procedures. The information will be used for research purposes. 
SIGNED     DATE 
WITNESS     DATE. 
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Appendix VII: Demographic data extraction sheet 
 
NAME OF PATIENT;   STUDY NUMBER; 
DATE OF BIRTH; 
HIV RESULTS: -  ELISA (IF >18 MONTHS OF AGE); 
PCR ( IF < 18 MONTHS OF AGE); 
INITIAL WHO CLINICAL STAGE; 
LABARATORY RESULTS PRESENT IN FILE: 
- FULL HAEMOGRAM: 
o White cell count  
 Total count 
 Polymorph percentage 
 Lymphocyte percentage 
 Monocyte percentage 
 Eisinophil percentage 
 Basophil percentage 
o Haemoglobin 
o Mean corpuscular volume 
o Mean corpuscular haemoglobin 
o Mean corpuscular haemoglopbin concentration 
 
- UREA & ELECTROLYTES: 
o Urea 
o Creatinine 
o Potassium 
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o Sodium 
o chloride 
- LIVER FUNCTION TESTS: 
o Alanine transferase 
o Aspartate transferase 
- CD4 COUNT: 
o Total 
o Percentage 
o CD4/CD8 ratio 
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Appendix VIII: Computer generated Bailey Report. 
 
Reason for Referral: 
 
 
Other Examiners: 
 
 
Composite Score Summary  
 
 
Composite 
Sum of 
Scaled 
Scores 
 
Composite 
Score 
 
Percentile 
Rank 
90%  
Confidence 
Interval 
 
Qualitative 
Description 
Cognitive 6 80 9 7589 Low Average 
Language 13 79 8 7487 Borderline 
Motor 12 76 5 7184 Borderline 
Social-Emotional 11 105 63 97112 Average 
General Adaptive 69 75 5% 72-78 Borderline 
Cognitive and Social-Emotional Composites are converted from their respective Scaled 
Scores. 
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Composite Score   Composite Score  
Cognitive 80   Social-Emotional 105  
Language 79   General Adaptive 75  
Motor 76      
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Subtest Score Summary  
 
Subtest 
Raw 
Score 
Scaled 
Score 
Cognitive (Cog) 66 6 
Receptive Communication (RC) 28 6 
Expressive Communication (EC) 35 7 
Fine Motor (FM) 42 6 
Gross Motor (GM) 58 6 
Social-Emotional (SE) 158 11 
Communication (Com) 45 6 
Community Use (CU) 25 6 
Functional Pre-Academics (FA) 40 11 
Home Living (HL) 43 7 
Health and Safety (HS) 50 9 
Leisure (LS) 47 7 
Self-Care (SC) 37 2 
Self-Direction (SD) 45 7 
Social (Soc) 52 7 
Motor (MO) 62 7 
 
 
Subtest Level Discrepancy Comparison  
 
 
Discrepancy Comparisons 
 
Scaled 
Score 1 
 
Scaled 
Score 2 
 
 
Diff. 
 
Critical 
Value 
Sig. 
Diff. 
Y/N 
 
Base 
Rate 
Cognitive vs. Receptive 6 6 0 2.98 N  
Cognitive vs. Expressive 6 7 -1 2.72 N 43.5% 
Cognitive vs. Fine Motor 6 6 0 2.95 N  
Cognitive vs. Gross Motor 6 6 0 2.61 N  
Cognitive vs. Social-Emotional 6 11 -5 2.70 Y 12.7% 
Receptive vs. Expressive 6 7 -1 3.06 N 41.2% 
Receptive vs. Fine Motor 6 6 0 3.27 N  
Receptive vs. Gross Motor 6 6 0 2.96 N  
Receptive vs. Social-Emotional 6 11 -5 3.05 Y 12.9% 
Expressive vs. Fine Motor 7 6 1 3.03 N 41.9% 
Expressive vs. Gross Motor 7 6 1 2.69 N 42.7% 
Expressive vs. Social-Emotional 7 11 -4 2.79 Y 17.7% 
Fine Motor vs. Gross Motor 6 6 0 2.93 N  
Fine Motor vs. Social-Emotional 6 11 -5 3.02 Y 13.7% 
Gross Motor vs. Social-Emotional 6 11 -5 2.68 Y 14.5% 
Statistical Significance (Critical Values) at the .05 level 
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Subtest Score   Subtest Score  
Cognitive (Cog) 6   Functional Pre-Academics (FA) 11  
Receptive Communication 
(RC) 
6   Home Living (HL) 7  
Expressive Communication 
(EC) 
7   Health and Safety (HS) 9  
Fine Motor (FM) 6   Leisure (LS) 7  
Gross Motor (GM) 6   Self-Care (SC) 2  
Social-Emotional (SE) 11   Self-Direction (SD) 7  
Communication (Com) 6   Social (Soc) 7  
Community Use (CU) 6   Motor (MO) 7  
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